drugset
drugset / Trial / NCT01251458

Hepatocellular Carcinoma (HCC)_Torisel_

NCT01251458 ↗

Phase 1/2 Completed 46 enrolled Chinese University of Hong Kong
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I/II study to evaluate dose limited toxicity and efficacy of Torisel

Timeline

Start
2009-10
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule — Intravenous

Indications

hepatocellular carcinoma